Squamous Cell Carcinoma News and Research

RSS

Squamous Cell Carcinoma is cancer that begins in squamous cells, which are thin, flat cells that look like fish scales. Squamous cells are found in the tissue that forms the surface of the skin, the lining of the hollow organs of the body, and the passages of the respiratory and digestive tracts. Also called epidermoid carcinoma.

Immunocompromised people are susceptible to skin cancer caused directly by beta-HPV

Researchers at the National Institutes of Health (NIH) have shown for the first time that a type of human papillomavirus (HPV) commonly found on the skin can directly cause a form of skin cancer called cutaneous squamous cell carcinoma (cSCC) when certain immune cells malfunction.

30 Jul 2025

New diagnostic test identifies head and neck cancer patients curable by surgery alone

Researchers developed a diagnostic test based on the LIMA1-alpha protein to distinguish patients with head and neck squamous cell carcinoma who can be cured with surgery alone, without the need for radiation or chemotherapy.

23 Jul 2025

Microbial signals rewire immunity in esophageal squamous cell carcinoma

Esophageal squamous cell carcinoma (ESCC) is a deadly cancer with particularly high prevalence in East Asia.

21 Jul 2025

AI tool predicts tumor aggressiveness using protein markers

As cancer cases have increased worldwide, the disease has become more complex, presenting challenges to scientific advances in diagnosis and treatment.

15 Jul 2025

FDA approval of pembrolizumab marks major shift in head and neck cancer treatment

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test.

15 Jun 2025

New data reveals insights into cancer and cardiovascular safety of JAK inhibitors

Now, the work presented at the 2025 annual EULAR congress in Barcelona adds two important pieces to the puzzle.

12 Jun 2025

CHAF1B drives lung squamous cell carcinoma progression by repressing SETD7

CHAF1B, a histone chaperone component of the chromatin assembly factor-1 complex, is overexpressed in multiple cancers and linked to tumor progression, but its role in lung squamous-cell carcinoma (LUSC) remained unclear.

11 Jun 2025

Two patients faced chemo. The one who survived demanded a test to see if it was safe.

JoEllen Zembruski-Ruple, while in the care of New York City's renowned Memorial Sloan Kettering Cancer Center, swallowed the first three chemotherapy pills to treat her squamous cell carcinoma on Jan. 29, her family members said. They didn't realize the drug could kill her.

4 Jun 2025

SWOG S2302 Pragmatica-Lung study demonstrates value of streamlined clinical trials in real world settings

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary question, finding that the investigational combination it tested did not significantly extend overall survival compared to standard of care treatments.

4 Jun 2025

Avelumab and cetuximab combination shows promise in phase II skin cancer trial

A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating that the combination of avelumab and cetuximab improved progression-free survival (PFS) compared to avelumab alone in patients with advanced cutaneous squamous cell carcinoma (cSCC).

1 Jun 2025

Combination treatment extends progression-free survival in advanced skin cancer

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the combination of the immunotherapy drug avelumab and targeted agent cetuximab had almost four times longer median progression-free survival compared to patients who received avelumab alone, according to the results of a phase 2 trial presented today at the American Society of Clinical Oncology (ASCO) meeting and concurrently published in the Journal of Clinical Oncology.

1 Jun 2025

Mass General Brigham researchers share cancer research discoveries at ASCO 2025

Researchers from Mass General Brigham will present research discoveries and outcomes from clinical trials in cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30-June 3, in Chicago.

30 May 2025

Study identifies C5aR1 as a key marker of metastasis in skin cancer

Researchers have identified C5aR1 as a novel biomarker for metastasis risk and poor prognosis in patients with cutaneous squamous cell carcinoma (cSCC), the most common type of metastatic skin cancer.

29 May 2025

Mutation profiles and clinicopathological correlations in lung squamous cell carcinoma

Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer.

26 May 2025

Blocking LSD1 restores immune response in early oral cancer

Oral squamous cell carcinoma (OSCC) is a leading cause of cancer-related deaths, and early detection is key to improving patient outcomes. However, the mechanisms driving the transition from preneoplastic lesions to full-blown cancer are not well understood.

11 May 2025

Targeting METTL3 may offer new hope for oral cancer treatment

A new research paper was published in Oncotarget, Volume 16, on May 8, 2025, titled "METTL3 promotes oral squamous cell carcinoma by regulating miR-146a-5p/SMAD4 axis."

11 May 2025

Study identifies key enzyme linked to metastasis in head and neck cancer

A recent study published in Engineering has shed new light on the mechanisms underlying the metastasis of head and neck squamous cell carcinoma (HNSCC).

8 May 2025

Study uncovers 'cell of origin' of the second most common lung cancer

The 'cell of origin' of the second most common lung cancer and the way that it becomes dominant in the lung have been discovered, in a new study in mice and humans from researchers at UCL, the Wellcome Sanger Institute and the University of Cambridge.

2 May 2025

Dana-Farber experts present innovative cancer studies at the 2025 AACR Annual Meeting

Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck cancer, metastatic breast cancer and lung cancer.

27 Apr 2025

lncRNAs shape the tumor microenvironment and drive cancer development

The tumor microenvironment (TME) is a complex and dynamic network consisting of tumor cells, immune cells, stromal cells, extracellular matrix (ECM), cytokines, and growth factors, all interacting to influence tumorigenesis, progression, and metastasis.

24 Apr 2025